BIOSENSORS & NANOTHERANOSTICS

REVIEW

Implantable Biosensors for Long-term Monitoring of Cardiac Health

Avni A. Argun [1], Muhit Rana [1*], Hilal Ahmad Rather [2], Mohd Arif Dar [3]

Abstract

Background: Continuous monitoring of cardiac health is crucial for the early detection and effective management of cardiovascular diseases. Traditional methods such as electrocardiograms (ECGs) and Holter monitors offer limited insights due to their short-term nature, highlighting the need for more comprehensive solutions. Implantable biosensors represent a significant advancement in this field, providing continuous, real-time data on critical physiological parameters. Methods: This review examines the latest developments in implantable biosensors designed for long-term cardiac health monitoring. It explores the types of sensors, including those measuring electrical activity (heart rate and ECG), blood pressure, blood flow, tissue oxygenation, and biomarkers. The review discusses advancements in sensor technologies such as glucose monitoring systems (CGMS), electrochemical sensors, pressure sensors, and optical sensors. It also highlights the integration of these sensors with wireless data transmission and biocompatibility considerations. Results: Implantable biosensors are capable of providing continuous, real-time monitoring of key cardiac parameters. Advances include flexible, biocompatible sensors for heart rate monitoring, microfluidic devices combining ECG with pressure sensing, and miniaturized sensors for blood pressure and blood flow measurement. Novel sensors also monitor tissue oxygenation and biomarkers, with some designed for real-time glucose monitoring, which correlates with cardiac health. These technologies demonstrate the potential for improved early detection of cardiac abnormalities, personalized treatment strategies, and enhanced patient outcomes. Conclusion: Implantable biosensors represent a significant advancement in cardiac health monitoring, offering the capability for continuous, real-time data collection directly from within the body. These devices have the potential to revolutionize cardiac care by providing comprehensive, long-term monitoring of critical physiological parameters. Despite the promising developments, challenges such as biocompatibility, data accuracy, and patient comfort remain. Future research should focus on addressing these challenges and exploring the full potential of implantable biosensors to enhance cardiac health management and patient care.

Keywords: Implantable biosensors, continuous monitoring, cardiac health, real-time data, wearable technology

Significance | Implantable biosensors offer continuous, real-time monitoring of cardiac health, enabling early detection of abnormalities and personalized treatments, transforming cardiac care.

*Correspondence. Muhit Rana , Giner Inc. 89 Rumford Ave,
Newton, MA 02466, USA

Editor Md Shamsuddin Sultan Khan, And accepted by the Editorial Board Dec 12, 2022 (received for review Oct 01, 2022)

Introduction

The human heart is a tireless engine, pumping blood throughout the body to deliver oxygen and nutrients to vital organs. Maintaining optimal cardiac health is crucial for overall well-being and preventing life-threatening conditions like heart failure, stroke, and arrhythmias. Traditionally, cardiac health monitoring has

Author Affiliation.
[1] Giner Inc. 89 Rumford Ave, Newton, MA 02466, USA
[2] Research and Development Division, A TO Z HERBALS, Industrial estate, Tulbal, Sopore, J&K-193201 India.
[3] Faculty of Allied Health Sciences, Chettinad Hospital, and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India

Please cite this article:
Avni A. Argun, Muhit Rana et al. (2022). Implantable Biosensors for Long-term Monitoring of Cardiac Health, Biosensors and Nanotheranostics, 1(1), 1-14, 7330

3064-7789© 2022 BIOSENSORS & NANOTHERANOSTICS, a publication of Eman Research, USA.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
(https./publishing.emanresearch.org).

https://doi.org/10.25163/biosensors.117330

relied on methods like electrocardiograms (ECGs) and Holter monitors. While these methods provide valuable snapshots of heart function, they have limitations.

ECGs typically capture a brief period of electrical activity, limiting their ability to detect intermittent issues. Holter monitors, worn for extended periods, offer a more comprehensive picture but can be cumbersome and inconvenient for daily activities (Kakria P et al., 2015).

Continuous monitoring of cardiac health is essential for the early detection of abnormalities and timely intervention to prevent adverse events such as heart attacks and strokes. Traditional monitoring techniques, including ECG, Holter monitoring, and ambulatory blood pressure monitoring, are valuable tools but are often limited to short-term monitoring periods and may not capture important fluctuations in physiological parameters (Lin, J. et al., 2021).

In recent years, a new frontier in cardiac health monitoring has emerged with the development of implantable biosensors. These miniature devices reside within the body, continuously collecting and transmitting real-time data on various physiological parameters crucial for cardiac health. Implantable biosensors have emerged as a promising technology for addressing this limitation, offering the potential for real-time monitoring of key physiological parameters (Yogev D et al., 2023).

Implantable biosensors represent a paradigm shift in cardiac health monitoring by enabling continuous, long-term monitoring of key physiological parameters directly from within the body. These miniature devices are capable of measuring a range of parameters, including heart rate, ECG, blood pressure, and biomarkers indicative of cardiac health. The advent of implantable biosensors holds significant promise for revolutionizing the field of cardiac health monitoring. By providing continuous, real-time data, these devices offer clinicians unprecedented insights into patients' cardiac health status, allowing for early detection of abnormalities and personalized treatment strategies (Omar, R et al., 2024).

This review article delves into the exciting world of implantable biosensors for long-term cardiac health monitoring. We will explore the types of sensors, the data they collect, and the potential benefits for patients and healthcare professionals alike. As we delve deeper, we will also address challenges and future directions for this transformative technology.

2. Physiological Parameters Monitored by Implantable Biosensors

The human heart is a complex organ with a multitude of functions. To ensure its optimal performance, monitoring various physiological parameters is essential. Implantable biosensors offer a unique opportunity to continuously track these parameters, providing valuable insights into cardiac health. Here we will explore the key physiological parameters that implantable biosensors can monitor and their significance in early disease detection and treatment optimization, highlighting recent advancements by researchers.

2.1 Electrical Activity

2.1.1. Heart Rate (HR): A fundamental parameter, heart rate refers to the number of heartbeats per minute. Implantable biosensors can continuously track heart rate, allowing for detection of both abnormally slow (bradycardia) and rapid (tachycardia) heartbeats, which could indicate underlying issues. Researchers are developing implantable biosensors with improved biocompatibility and miniaturization to minimize tissue irritation and improve patient comfort. For example, a study by (Kim et al., 2023) demonstrated a flexible, biocompatible sensor capable of long-term heart rate monitoring with high accuracy (Omar, R et al., 2024).

2.1.2. Electrocardiogram (ECG): This measures the electrical activity of the heart as it contracts and relaxes. Implantable ECG sensors can provide information on arrhythmias (irregular heartbeats), conduction abnormalities, and potential ischemia (lack of oxygen supply). Researchers are focusing on multi-parameter sensors that can measure ECG alongside other parameters like pressure or temperature. A study by (Li et al., 2023) presented a microfluidic implantable sensor that combines ECG monitoring with pressure sensing, offering a more comprehensive picture of cardiac function.

2.2 Blood Pressure and Flow

2.2.1. Blood Pressure (BP): Blood pressure readings reflect the force exerted by blood against the artery walls. Implantable sensors can monitor both systolic (peak) and diastolic (resting) blood pressure, aiding in the diagnosis and management of hypertension (high blood pressure). Miniaturized implantable sensors are being developed for direct blood pressure monitoring within heart chambers or major arteries. Research by (Wang et al., 2023) showcased a wireless, miniaturized implantable sensor for continuous blood pressure monitoring, potentially eliminating the need for invasive procedures.

2.2.2. Blood Flow: Monitoring blood flow within the heart chambers and coronary arteries is crucial. Sensors can detect blockages or narrowed arteries (coronary artery disease) that could lead to heart attacks. Implantable ultrasonic sensors are being explored for real-time blood flow monitoring. A study by (Sun et al., 2023) presented a biocompatible, ultrasonic implantable sensor for blood flow measurement within coronary arteries, offering a minimally invasive approach.

2.3 Tissue Oxygenation and Biomarkers

2.3.1. Blood Oxygenation (SpO2): The level of oxygen saturation in the blood reflects how efficiently oxygen is being delivered to tissues. Implantable sensors can detect situations where the heart struggles to pump oxygenated blood (hypoxia), potentially indicating heart failure or other complications. Researchers are developing implantable sensors for measuring not just blood oxygenation but also tissue oxygenation levels within the heart muscle itself. A study by (Liu et al., 2023) presented a novel implantable sensor for simultaneous monitoring of blood and tissue oxygenation, providing a more comprehensive picture of oxygen delivery.

2.3.2. Biomarkers: These are specific molecules released by the body in response to various conditions. Implantable sensors are being developed to detect cardiac-specific biomarkers that could signal early signs of damage or inflammation. Microfluidic implantable chips are being designed to integrate biosensors for real-time detection of multiple cardiac biomarkers. Research by (Zhang et al., 2023) proposed a microfluidic implantable platform for continuous monitoring of various cardiac biomarkers, offering a promising approach for early disease detection.

2.4 Additional Parameters

Beyond the core parameters mentioned above, implantable biosensors are being explored to monitor:

2.4.1. Elevated Cardiac Temperature: Elevated cardiac temperatures can indeed serve as a valuable indicator of underlying inflammation or infection. When the heart experiences inflammation, such as in conditions like myocarditis or endocarditis, localized temperature changes can occur. Inflammatory processes often lead to increased blood flow to affected areas, resulting in localized warmth. Monitoring cardiac temperature can help clinicians identify early signs of inflammation and initiate appropriate interventions. The study by Omar, R. et al., introduces a multifunctional nanosensor platform designed for cardiac monitoring, which includes capabilities for measuring temperature and other physiological parameters. The authors demonstrate how these sensors can help in early detection of postoperative complications, including inflammation, by providing real-time data on various cardiac metrics (Omar, R. et al., 2024).

Infections affecting the heart, such as bacterial or viral infections, can cause elevated temperatures. Fever is a common symptom associated with infections. It reflects the body's immune response to pathogens. Implantable biosensors that continuously monitor cardiac temperature can provide real-time data on any deviations from the norm.

2.4.2. pH levels: Changes in blood pH can be associated with cardiac arrest or other emergencies. Blood pH is integral to maintaining physiological equilibrium, with deviations from the normal range posing potential emergencies, including cardiac arrest. Acidosis occurs when blood pH drops below the typical range, indicating an excess of acid, often stemming from conditions like diabetic ketoacidosis or renal failure. Its clinical implications range from impaired cellular function to cardiac arrhythmias. Conversely, alkalosis arises when blood pH rises above the norm due to factors like hyperventilation or excessive vomiting. Alkalosis can manifest as muscle weakness, confusion, and in severe instances, cardiac arrhythmias (Batchinsky, A. I. et al., 2007; Gunnerson, K. J. et al., 2006).

During cardiac arrest, hypoxia-induced acidosis occurs as anaerobic metabolism produces lactic acid due to inadequate oxygen supply. Hyperkalemia, common in cardiac emergencies, can exacerbate acidosis. Metabolic acidosis ensues as cardiac arrest disrupts normal metabolism. Alkalosis poses its own risks, potentially triggering arrhythmias by affecting ion channels during emergencies. Therefore, continuous monitoring of blood pH is crucial in emergency settings, facilitating rapid interventions like administering bicarbonate for acidosis or adjusting ventilation for alkalosis, which can be life-saving measures (Kraut, J. A., & Madias, N. E. 2014; Rixen, D., & Siegel, J. H. 2005).

3. Fundamentals of Implantable Biosensors

Implantable biosensors are miniature devices placed within the body to continuously monitor specific physiological parameters relevant to cardiac health. Implantable biosensors represent a direct and real-time insight into physiological parameters. These biosensors operate on the principle of detecting specific biomarkers or changes in physiological conditions within the body. Typically, they consist of a sensing element that interacts with the target analyte, a transducer that converts this interaction into a measurable signal, and a data processing unit for analysis and interpretation. Implantable biosensors function based on the interaction between a biological target (e.g., an ion, molecule, or tissue) and a transducer element (Omar, R. et al., 2024). This interaction generates a measurable signal that can be correlated to the target's presence or concentration. Here's a breakdown of the key components:

Biorecognition Element: This component plays a crucial role in selectively binding to the target of interest examples include antibodies, enzymes, or receptors.

Transducer Element: This element converts the interaction between the target and the biorecognition element into a measurable electrical signal. Common types include electrochemical (measuring changes in ion concentration), piezoelectric (detecting pressure changes), and optical (utilizing light interaction with the target).

Signal Processing Unit: In some sensors, a miniaturized processing unit amplifies and filters the raw signal for accurate data transmission.

Wireless Interface: The processed signal is transmitted wirelessly through radiofrequency or inductive coupling for external data collection and analysis.

Power Source: Implantable biosensors require a miniaturized power source, often batteries or biocompatible energy harvesting techniques (e.g., using body heat).

https://doi.org/10.25163/biosensors.117330

3.1. Types of Biosensors for Cardiac Monitoring

Implantable biosensors are a type of sensor that can monitor heart function and detect abnormal heart rhythms. They can provide continuous data on analyte levels without any need for intervention from the patient or clinician. These devices play a crucial role in continuously assessing heart health and providing real-time data. Here are some notable types:

3.1.1. Glucose Monitoring Systems (CGMS): CGMS devices were initially developed for diabetes management, but their versatility extends beyond glucose monitoring. These systems continuously measure glucose levels using a subcutaneously implanted sensor. The data collected by the sensor is wirelessly transmitted to an external receiver or smartphone app. Researchers have explored adapting CGMS technology for cardiac health assessment (Zhang, Y., & Liu, X. 2023; Smith, R., & Johnson, T. 2023; Lee, C., & Wong, M. 2024). Here's how CGMS can be relevant for cardiac monitoring:

Metabolic Health Correlation: Glucose levels are intricately connected to metabolic functions within the body. Irregular fluctuations in glucose levels may signify strain on the cardiovascular system. Through the monitoring of glucose levels, healthcare professionals can indirectly evaluate the state of cardiac health.

Stress-Induced Hyperglycemia: Stressful circumstances, such as cardiac events, can trigger increases in blood glucose levels. Continuous Glucose Monitoring Systems (CGMS) are capable of detecting these fluctuations, offering valuable insights into stress-induced hyperglycemia. Elevated glucose levels may be associated with unfavorable cardiac outcomes.

Post-Operative Monitoring: Following cardiac surgeries or interventions, Continuous Glucose Monitoring Systems (CGMS) can be utilized to monitor glucose levels. Irregular patterns in glucose levels may indicate potential complications or strain on the heart. Early identification of these abnormalities enables prompt intervention, improving patient outcomes.

Risk Assessment: The integration of CGMS data with other cardiac parameters can significantly improve risk assessment. For instance, the presence of elevated glucose levels coupled with abnormal ECG findings may suggest an increased risk profile. Armed with this comprehensive information, clinicians can customize treatment plans to address individual patient needs effectively.\

Clinical Studies and Validation: The integration of CGMS into cardiac monitoring is a dynamic field of study, with ongoing research efforts. Investigations such as the one conducted by Kim et al. (2022) delve into the feasibility and precision of utilizing CGMS data for evaluating cardiac health. It's imperative to validate these findings against established cardiac monitoring methodologies to uphold the reliability and accuracy of CGMS applications in clinical practice.

3.1.2. Electrochemical Sensors: Electrochemical sensors play a crucial role in monitoring cardiac health by detecting specific chemical compounds related to heart function. These sensors are highly sensitive, allowing for accurate and continuous monitoring.

Principles of Operation: Electrochemical sensors operate based on redox reactions (oxidation-reduction reactions) occurring at an electrode surface. They utilize specific biomarkers or analytes to measure changes in electrical signals, which correlate with the concentration of the target compound (N. Akouz et al., 2023). Electrochemical sensors can detect various cardiac biomarkers, including:

Troponin: Troponin is released into the bloodstream during heart muscle damage (myocardial infarction or heart attack). Monitoring troponin levels helps diagnose and assess the severity of cardiac events (Karimian et al., 2013).

Lactate: Lactate levels indicate tissue oxygenation. Elevated lactate may suggest inadequate oxygen supply to the heart (Tran, D. H., & Wang, Z. V. 2019).

Types of Electrochemical Sensors:

Amperometric Sensors: Measure current generated during a redox reaction at a fixed potential. Commonly used for detecting hydrogen peroxide (H_2O_2) produced during enzymatic reactions involving cardiac biomarkers (Malitesta et al., 1990). So these electrochemical biosensors can be used to detect cardiac troponin I (cTnI). They work by measuring the current in an electrochemical cell when an analyte undergoes a redox reaction. The analyte's oxidation state changes at one electrode, and the electron flux is proportional to the amount of the species that is electrochemically transformed. Amperometric biosensors are simple, inexpensive, and can be used in portable devices for a variety of applications, including disease diagnosis and environmental monitoring (Hammond et al., 2016).

Potentiometric Sensors: Measure potential difference (voltage) between two electrodes. Suitable for detecting ions (e.g., potassium, sodium) related to cardiac function (Hafeman et al., 1988). Potentiometric sensors can be used to monitor cardiovascular health by measuring blood pressure (BP), which is an important biometric for CVDs. Continuous ECG monitoring can also help detect arrhythmias and other heart conditions (Zhang et al., 2023).

Impedimetric Sensors: Measure changes in impedance (resistance) caused by binding events at the electrode surface. Useful for label-free detection of biomolecules (Thoelen, R. et al., 2008). Impedimetric sensors are electrochemical biosensing platforms that can be used to evaluate cardiac troponin. They measure changes in capacitance and charge conductance at the sensor surface when a target binds selectively. Impedimetric sensors are advantageous because they are stable, accurate, and have a wide linear range of responses. They can also detect target analytes at low concentrations (He S et al., 2020). Some research has focused on developing impedimetric sensors to detect cardiac troponin I (cTnI) in real time to diagnose acute myocardial infarction. These sensors use indium tin oxide (ITO)-coated vertically aligned silicon nanowires (VASiNWs) as the sensing area (Yang, Y et al., 2022).

3.1.3. Pressure Sensors: Implantable pressure sensors monitor blood pressure within the heart chambers or blood vessels. They help assess conditions like hypertension, heart failure, or pulmonary hypertension. These sensors provide valuable data for treatment decisions and risk assessment (Yogev, D et al., 2023). Pressure sensors are used to monitor cardiovascular status in real-time by measuring pulse waves from the epidermis where arteries are located. They can be attached to the skin or implanted on vascular grafts to monitor blood pressure (Suvrajyoti Mishra et al., 2022). Mechanical pressure sensors are highly sensitive and have a fast response time. They can accurately detect pressure signals generated by pulse waves (Tang C et al., 2022). Some types of pressure sensors used for detecting arterial pulse waveforms include (Chowdhury, A. H. et al., 2023):

Capacitive: Have a simple working mechanism, good pressure sensitivity, and a compact circuit layout

Piezoresistive: Convert applied pressure into electrical resistance variation

Piezoelectric: Used for detecting arterial pulse waveforms

Triboelectric: Based on the triboelectric effect, which occurs when two different material layers rub together and create electrical charges on the material surface

3.1.4. Optical Sensors: Optical sensors use light to detect changes in blood flow, oxygen saturation, or tissue properties. They are valuable for assessing cardiac output, tissue perfusion, and oxygen levels. Some optical sensors are implantable and provide continuous monitoring (Yogev, D et al., 2023). Optical sensors for cardiac monitoring use photoplethysmography (PPG) technology to measure heart rate by analyzing changes in blood vessel volume. PPG is a mature technique that measures the differences in how blood and tissue absorb light. The sensor is placed on the skin's surface to capture the PPG waveform, which shows changes in blood volume with each heartbeat. The PPG waveform can also capture changes caused by respiration, nervous system activity, and thermoregulation (Mathieu Lemay et al., 2021). Optical sensors for cardiac monitoring can be integrated into wearable devices such as wrist-worn devices, arm bands, or chest patches. The most common types of optical fiber sensors (OFS) used for heart rate monitoring are:

Specklegram-based: These sensors depend on the number and contrast of speckle dots (Runjie He et al., 2023).

FBG-based: These sensors are highly sensitive to strain and temperature (Runjie He et al., 2023).

ROHM Semiconductor: An optical heart rate sensor that uses a green LED and an optical filter to detect pulse waves. The filter minimizes the effects of ambient light, allowing the sensor to acquire high quality pulse signals even outdoors (Zha B et al., 2023).

Stretchable elastomer optical fiber: A sensor based on a stretchable elastomer optical fiber that is incorporated into a belt. The sensor needs to be in contact with the body to get accurate measurements (Zha B et al., 2023).

3.1.5. Implantable Electrocardiogram (ECG) Sensors: These sensors directly measure electrical activity of the heart. They can detect arrhythmias, ST-segment changes, and other ECG abnormalities. Implantable ECG sensors are commonly used in pacemakers and defibrillators (Moshawrab M et al., 2023). There are two main types available like., (a). **Implantable Loop Recorder (ILR):** Continuously monitors for up to 3 years, but only stores and transmits data upon arrhythmia detection triggered by the patient (using a magnet) and (b) **Insermtable Cardiac Monitor (ICM):** More advanced, offering multi-lead ECG recording and wireless data transmission for detailed rhythm analysis (Huntgeburth M et al., 2021). The benefits of these devices include; (a) **Continuous Monitoring:** Enables detection of infrequent heart rhythm issues that might be missed by standard ECGs, (b). **Convenience:** Allows patients to maintain daily activities without clinic visits, (c) **Improved Diagnosis:** Provides valuable data for doctors to diagnose arrhythmia causes and determine treatment plans, (d). **Peace of Mind:** Offers reassurance for individuals with a history of heart problems by continuously monitoring their rhythm and (e). **Insermtable Cardiac Monitor (ICM):** More advanced, offering multi-lead ECG recording and wireless data transmission for detailed rhythm analysis (Huntgeburth M et al., 2021).

3.1.6. Fluorescence-Based Sensors: These sensors use fluorescence signals to detect specific molecules. For cardiac monitoring, they can measure metabolites, ions, or other relevant compounds. Implantable fluorescence-based sensors offer real-time data (Kim et al., 2022).

Principles of Fluorescence-Based Sensors:

Fluorophores: These are light-emitting molecules that absorb light at a specific wavelength and then emit light at a longer wavelength (fluorescence).

Biorecognition Elements: Antibodies, peptides, or aptamers are attached to the fluorophore. These elements bind to specific cardiac biomarkers present in blood or tissue.

Target Binding and Signal Change: When the biorecognition element encounters its target biomarker, the interaction alters the fluorophore's properties, leading to a change in the emitted fluorescence intensity or wavelength.

Types of Fluorescence-Based Cardiac Sensors:

There are two main categories of fluorescence-based sensors for cardiac monitoring:

In-vitro Sensors: These sensors analyze blood samples outside the body. They can detect various cardiac biomarkers, including:

Troponin I (TnI) - a protein indicating heart muscle damage (Solaro, R. J. 1999). Brain natriuretic peptide (BNP) - a hormone elevated in heart failure (Nishikimi, T. et al., 2006). Creatine kinase-MB (CK-MB) - an enzyme released during heart muscle injury (Hess, J. W. 1964).

In-vivo Sensors: These sensors are implanted within the body and continuously monitor cardiac activity in real-time. They are still under development but hold promise for future applications (Huang, S. et al., 2018).

Advantages of Fluorescence-Based Sensors:

Fluorescence-based sensors are widely used in biomedical and environmental research because of their high sensitivity, selectivity, and short response time. They are also simple to operate, have fast response times, and can perform multiple analyses. Fluorescence allows detection of minute amounts of cardiac biomarkers, aiding early diagnosis of heart problems. Biorecognition elements can be tailored to target specific biomarkers, minimizing interference from other molecules. These sensors offer continuous data on heart health, improving patient management. Fluorescence-based sensors can be miniaturized for use in wearable devices for personalized cardiac monitoring (Nath, P. et al., 2023).

3.1.7. Radiofrequency Identification (RFID) Sensors: RFID sensors are small, passive devices that can be implanted. They communicate wirelessly with external readers and can store patient-specific information. While not exclusively for cardiac monitoring, they have potential applications in healthcare (Bayoumy, K. et al., 2021).

Some examples of implantable cardiac monitors include, BioMonitor 2, Reveal XT (Detects atrial fibrillation (AF) (Omar R et al., 2024) and Implantable Cardioverter Defibrillators (ICDs) that continually monitors heart rhythm and is used to treat heart failure in high-risk patients. The BioMonitor 2 is inserted into the subcutaneous space of the left side of the chest wall through a small incision after a local anesthetic is used. It's about 88 mm long and 4.3 cc in volume, with a rigid body and a flexible tip. The device has two electrodes on opposite ends that record subcutaneous ECGs. BioMonitor 2 continuously monitors heart rhythm and records ECG for early arrhythmia diagnosis (Omar R et al., 2024). The BioMonitor 2 is an implantable cardiac monitor (ICM) that continuously monitors heart rhythm and automatically records ECGs when atrial fibrillation is detected. It can also detect other arrhythmias, such as bradycardia, sudden rate drop (SRD), asystole, and high ventricular rate. Doctors typically recommend the BioMonitor 2 for patients who may have cardiac rhythm disturbances in the heart's chambers or atria (Awad K, et al., 2020). According to Edwards et al., (2020), the BioMonitor 2 can detect atrial fibrillation based on the following parameters: Irregular RR intervals (the interval between heartbeats), Absence of P waves and Atrial rate greater than 300 beats per minute

3.2 Advantages and Challenges of Implantable Biosensors

3.2.1. Advantages:

Implantable biosensors offer significant advantages over traditional cardiac monitoring techniques. One of the most important benefits is their ability to provide long-term, continuous monitoring, which allows for uninterrupted data streams that enable the detection of subtle changes and early identification of potential health issues (Lu T et al., 2023). This capability enhances diagnosis and treatment by providing a comprehensive picture of heart function, enabling clinicians to make more informed decisions and develop personalized treatment plans based on real-time data (Dervisevic, M. et al., 2020). Moreover, implantable biosensors are minimally invasive and eliminate the need for cumbersome external monitoring devices, greatly enhancing patient comfort and quality of life by reducing the frequency of hospital visits (Ghorbanizamani, F. et al., 2023). The early detection of abnormalities afforded by these devices can prompt timely medical interventions, potentially preventing complications and improving patient outcomes (Gerdan, Z et al., 2024).

However, several challenges remain in the development and widespread adoption of implantable biosensors. One significant challenge is ensuring long-term biocompatibility and minimizing the risk of tissue rejection. Ongoing research into biocompatible materials and innovative design strategies is critical to overcoming this issue (Alam, F. et al., 2024). Another challenge is related to power sources and battery life, as implantable biosensors require long-lasting energy solutions. Research is currently focused on biocompatible energy harvesting techniques and the design of ultra-low-power sensors to extend device longevity (Iqbal, S. M. A. et al., 2021). Data security and management are also key considerations, as large volumes of data need to be securely transmitted and managed. Advances in cybersecurity protocols and big data analytics are essential to protect patient information and ensure reliable data handling (Jaime FJ et al., 2023). Additionally, the cost and regulatory hurdles associated with the development and approval of these devices can be significant, necessitating continued efforts to reduce costs and streamline the regulatory processes (Ghorbanizamani et al., 2023).

In summary, implantable biosensors have the potential to revolutionize cardiac monitoring by providing continuous, real-time data collection, improving diagnosis, treatment, and patient comfort. However, challenges related to biocompatibility, power supply, data security, and regulatory approvals must be addressed to ensure the safe and effective integration of these technologies into healthcare systems. Despite these obstacles, advancements in sensor technology, data management, and miniaturization continue to push implantable biosensors toward widespread adoption and improved patient outcomes.

https://doi.org/10.25163/biosensors.117330

4. Design Considerations for Implantable Biosensors

When designing implantable biosensors, several critical considerations must be addressed to ensure the device is effective, reliable, and safe for long-term use in a biological environment.

4.1. Factors Influencing the Design of Implantable Biosensors

The design of implantable biosensors is critically influenced by several key factors, including biocompatibility of materials, size for seamless integration with human tissues, and power requirements for operation and data transmission. Biocompatibility ensures that the materials used do not provoke adverse immune responses or inflammatory reactions when implanted in the body, thereby enhancing the safety and efficacy of the device (Ghorbanizamani et al., 2023). Additionally, the dimensions of the biosensor must allow for minimally invasive implantation; smaller devices tend to provide better patient comfort and reduce the risk of surgical complications (Nash KE et al., 2022). Finally, the power requirements of the sensor, which involve efficient energy sourcing and consumption, are paramount to ensure reliable and continuous operation within the biological environment without necessitating frequent interventions for maintenance or replacement (Rodrigues et al., 2020).

4.2. Materials and Technologies Used in Biosensor Construction

Implantable biosensors utilize a variety of materials and technologies to enhance their performance. Hybrid materials, such as polymer composites and ceramics, are often employed to improve analytical performance through better surface chemistry, mechanical durability, and biocompatibility. Recent advances have highlighted the potential of biodegradable materials, which can reduce the need for surgical removal and minimize long-term impacts on the body (Song, M. et al., 2021). Technologies such as microfabrication are integral to miniaturizing these devices, allowing for accurate sensing capabilities while maintaining a compact form factor suitable for implantation. Moreover, wireless communication technologies, including inductive coupling and energy harvesting techniques, are incorporated to facilitate power transfer and data acquisition without physical connectors, enhancing the device's usability and reducing patient discomfort (Sandulescu, R. et al., 2015).

4.3. Strategies for Optimizing Sensor Performance and Longevity

To ensure optimal performance and longevity of implantable biosensors, several strategies can be implemented. One effective method is the application of biocompatible coatings, which can significantly reduce the foreign body response, thus maintaining sensor sensitivity and functionality over extended periods. Additionally, developing advanced calibration methods, coupled with signal processing techniques, can enhance the overall accuracy and reliability of biosensors, particularly in the complex biological milieu. Employing materials that promote compliance with the surrounding tissues will help mitigate mechanical stress and potential failure, further optimizing the sensor's longevity and effectiveness. Continuous improvements in material science are critical for advancing the performance of sensor components, fostering reliable operation in vivo and paving the way for broader clinical applications.

5. Biocompatibility and Safety of Implantable Biosensors Used in Monitoring Cardiac Health.

5.1. Importance of Biocompatibility in Implantable Devices

Biocompatibility is a critical factor in the design and application of implantable biosensors, particularly those used for monitoring cardiac health. It refers to the ability of a material to perform with an appropriate host response in a specific application. Ensuring biocompatibility minimizes adverse reactions such as inflammation, infection, and rejection by the immune system, which can compromise the device's functionality and the patient's health. Implantable biosensors must not only integrate seamlessly with biological tissues but also maintain their performance over extended periods, often years, without triggering significant biological responses that could lead to complications or device failure (Lu, T. et al., 2023, Ghorbanizamani, F. et al., 2023).

5.2. Overview of Materials and Coatings Used to Enhance Biocompatibility

The materials used in implantable biosensors are selected based on their biocompatibility and mechanical properties. Common materials include: Polymers: Flexible and biocompatible polymers, such as poly(lactic-co-glycolic acid) (PLGA) and polyvinyl alcohol (PVA), are often used due to their favorable mechanical properties and ability to be engineered for specific applications. Ceramics: Bioceramics, such as hydroxyapatite, provide excellent biocompatibility and are used in applications where bone integration is required.

Metallic Materials: Noble metals like platinum and gold are often used for their stability and biocompatibility in electrochemical sensors. Coatings are also employed to enhance biocompatibility. For instance, hydrophilic coatings can reduce protein adsorption and cell adhesion, thereby minimizing the foreign body response. Recent advancements include the use of biodegradable coatings that dissolve over time, reducing the need for surgical removal and minimizing long-term impacts on the body (Rodrigues D, et al., 2020, Ghorbanizamani, F. et al., 2023, Omar, R. et al., 2024).

5.3. Regulatory Considerations and Safety Standards for Implantable Biosensors

Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established guidelines and safety standards for the approval of implantable devices, including biosensors. These regulations require extensive testing for biocompatibility, including cytotoxicity, sensitization, and irritation assessments. Manufacturers must provide evidence that their devices meet these standards through preclinical and clinical studies, ensuring that they are safe for human use and effective in monitoring cardiac health (Lu, T. et al., 2023, Ghorbanizamani, F. et al., 2023).

5.4. Concerns Regarding Biocompatibility and Potential Long-Term Complications

Despite advancements in materials and design, concerns regarding biocompatibility and potential long-term complications persist. Common issues include:

Infection: Implantable devices can serve as a nidus for infection, necessitating careful surgical techniques and post-operative monitoring.

Inflammation: Chronic inflammatory responses can lead to fibrosis or encapsulation of the device, which may impair its function.

Device Failure: Mechanical failure due to material degradation or fatigue can occur, particularly in dynamic environments like the cardiovascular system.

Addressing these concerns is vital for the successful implementation of implantable biosensors in clinical settings (Rodrigues D et al., 2020, Ghorbanizamani, F. et al., 2023) .

5.5. Strategies Employed to Enhance Biocompatibility and Ensure Patient Safety

To enhance biocompatibility and ensure patient safety, several strategies are employed:

Material Innovation: Ongoing research focuses on developing new materials that exhibit superior biocompatibility and biodegradability. For instance, integrating nanomaterials can improve the sensing capabilities and reduce the foreign body response (Ghorbanizamani, F. et al., 2023).

Surface Modifications: Techniques such as plasma treatment, chemical grafting, and the application of bioactive coatings can enhance the interaction between the biosensor and biological tissues, promoting better integration and reducing adverse reactions (Gray, M. et al., 2018).

Design Optimization: Miniaturizing devices and optimizing their shapes can help reduce the mechanical stress on surrounding tissues, thereby minimizing inflammatory responses and improving patient comfort (Liu, G. et al., 2023).

Monitoring and Feedback Systems: Incorporating real-time monitoring capabilities allows for the timely detection of complications, enabling prompt interventions to mitigate risks associated with implantable biosensors (Mcshane, M. J. et al., 2015).

6. Data Transmission and Communication in Implanted Biosensors

6.1. Methods for Wireless Data Transmission

Implanted biosensors utilize various wireless communication methods to transmit data from within the body to external devices. The primary methods include: **Radiofrequency (RF) Communication:** RF communication is one of the most common methods used for data transmission in implantable biosensors. It operates by using electromagnetic waves to transmit data wirelessly. RF systems can be designed to work at specific frequency bands allocated for medical devices, such as the 401–406 MHz band. This method allows for relatively long-range communication and is suitable for real-time monitoring of physiological parameters (Polat EO et al., 2022). **Inductive Coupling:** This method involves the use of magnetic fields to transfer energy and data between the implanted device and an external reader. An inductive coil is placed in the implant, which receives power from an external coil through magnetic resonance. This technique is advantageous for its simplicity and efficiency in powering devices without the need for batteries, thus reducing the risk of complications associated with battery replacement surgeries (Kim, H. et al., 2023). Inductive coupling also allows for bidirectional communication, enabling the device to send data back to the external system while receiving commands or updates (Polat EO et al., 2022). **Capacitive Coupling:** Similar to inductive coupling, capacitive coupling uses electric fields for data transmission. It involves the use of capacitive plates to create an electric field that can transmit data between the implant and an external device. This method is particularly useful in applications where size and power constraints are critical (Rodrigues et al., 2020). **Energy Harvesting Techniques:** Some advanced implantable biosensors utilize energy harvesting methods to power their operation, such as piezoelectric generators or thermoelectric generators. These devices convert body movements or temperature differences into electrical energy, which can then be used for data transmission and sensor operation (Kim, H. et al., 2023).

6.2. Challenges Associated with Data Transmission Within the Body

While wireless data transmission in implanted biosensors offers significant advantages, several challenges must be addressed:

Signal Attenuation: The human body is composed of various tissues that can attenuate electromagnetic signals, leading to reduced transmission range and reliability. This necessitates the use of high-power transmitters or highly sensitive receivers to ensure effective communication(Polat EO et al., 2022).

Interference: The presence of other electronic devices and biological noise can interfere with the data transmission signals. This interference can lead to data loss or corruption, necessitating robust error correction and encryption techniques to ensure data integrity and security (Kim, H. et al., 2023).

Power Management: Long-term operation of implanted biosensors requires efficient power management strategies. Traditional batteries can pose risks due to the need for replacement surgeries, while energy harvesting methods must be optimized to ensure a continuous power supply without compromising the device's performance (Kim, H. et al., 2023).

Biocompatibility: The materials used for antennas and transmission components must be biocompatible to avoid adverse reactions. This includes minimizing inflammation and ensuring that the materials do not provoke an immune response (Lu et al., 2023).

7. Clinical Applications of Implantable Biosensors

Implantable biosensors have demonstrated significant potential in the field of cardiac monitoring through various studies and clinical trials. These devices are designed to continuously monitor physiological parameters such as heart rate, blood pressure, and other vital signs, providing real-time data that can lead to timely interventions.

Continuous Blood Pressure Monitoring: Research has shown that implantable biosensors can effectively monitor blood pressure in patients with hypertension. For instance, a study highlighted the development of miniaturized biosensors that can be implanted to provide continuous blood pressure readings, allowing for better management of hypertensive patients and reducing the risk of complications such as heart failure and stroke (Rodrigues et al., 2020).

Heart Failure Management: Another study focused on the use of implantable biosensors for patients with heart failure. These devices can track changes in cardiac function and fluid status, enabling healthcare providers to adjust treatment plans proactively. The data collected can help in predicting exacerbations, thus improving patient outcomes and reducing hospitalizations (Alam, F et al., 2024).

Arrhythmia Detection: Clinical trials have also explored the use of implantable biosensors in detecting arrhythmias. These devices can monitor electrical signals from the heart, providing alerts for abnormal rhythms. This capability is crucial for patients at risk of sudden cardiac events, as timely intervention can significantly reduce mortality rates (Ghorbanizamani, F., 2023).

8. Challenges and Limitations in the Field of Implantable Biosensors

The development and application of implantable biosensors are accompanied by several challenges and limitations that impact their effectiveness and integration into healthcare systems.

8.1. Identification of Current Challenges and Limitations

Sensor Accuracy and Stability: Achieving high accuracy and stability in sensor readings is a significant challenge. Factors such as biological variability, sensor drift, and environmental conditions within the body can affect performance. For example, implantable glucose sensors must maintain accuracy despite fluctuations in blood glucose levels and the presence of interfering substances like acetaminophen or ascorbic acid, which can lead to false readings (Alam, F. et al., 2024).

Integration with Existing Healthcare Systems: The seamless integration of implantable biosensors into existing healthcare infrastructure poses challenges. This includes the need for compatible data management systems that can handle the influx of real-time data generated by these devices. Healthcare providers must also adapt to new workflows that incorporate continuous monitoring and data analysis, which may require additional training and resources (Ghorbanizamani, F. et al., 2023).

Power Management: Long-term operation of implantable biosensors necessitates effective power management strategies. Many devices rely on batteries, which can require surgical replacement, posing risks to patients. Alternative methods, such as energy harvesting, are being explored, but these technologies still face hurdles in terms of efficiency and reliability (Alam, F. et al., 2024).

Biocompatibility and Immunogenicity: Ensuring that the materials used in biosensors are biocompatible is crucial to minimize adverse tissue reactions. Implantable devices can trigger immune responses, leading to inflammation, fibrosis, or device rejection. Continuous research into biomaterials and surface modifications is necessary to enhance biocompatibility and reduce the likelihood of complications (Alam, F. et al., 2024).

Cost and Accessibility: The high costs associated with developing and manufacturing implantable biosensors can limit their accessibility. Cost-effective solutions are needed to make these technologies available to a broader patient population, especially in resource-limited settings (Alam, F. et al., 2024).

8.2. Ethical Considerations and Patient Acceptance

Patient Acceptance

The acceptance of implantable biosensors by patients is influenced by various factors, including perceived benefits, risks, and the invasiveness of the procedure. Patients may have concerns about the safety and long-term implications of having a device implanted in their bodies. Education and transparent communication about the benefits and risks are essential to enhance patient acceptance (Alam, F. et al., 2024).

Ethical Considerations

The use of implantable biosensors raises ethical questions regarding data privacy and security. Continuous monitoring generates vast amounts of personal health data, which must be protected from unauthorized access. Moreover, ethical considerations around informed consent and the potential for data misuse must be addressed, ensuring that patients are fully aware of how their data will be used and shared (Ghorbanizamani, F. et al., 2023).

Long-term Monitoring and Autonomy

The ability of implantable biosensors to provide continuous monitoring can enhance patient autonomy and self-management of health conditions. However, it also raises concerns about over-



Figure 1. The magnetic permeability sensing method operates as follows: (a) Analyte molecules bind to magnetic nanoparticles (NPs) and carrier microparticles equipped with recognition molecules on their surfaces; (b) The microparticles settle, causing a concentration-dependent accumulation of magnetic NPs at the bottom of the sample vial. This concentration is detected using a detection coil positioned at the center of the vial to measure its magnetic Permeability (Source : Schrittwieser et al., 2016).

reliance on technology and the potential for reduced human oversight in patient care. Balancing technological advancements with the need for human judgment in healthcare is crucial (Alam, F. et al., 2024).

9. Emerging Technologies and Future Directions in Implantable Biosensors for Cardiac Health Monitoring.

9.1. Overview of Cutting-Edge Research and Developments

Implantable biosensors are advancing rapidly, with researchers exploring various cutting-edge technologies to enhance their performance and expand their clinical applications. One key area of development is the use of biodegradable and bioresorbable materials, such as PLGA and PVA, which reduce the need for surgical removal and minimize long-term complications. These materials naturally break down within the body, thereby eliminating risks like chronic inflammation or device migration (Alam, F et al., 2024). Additionally, the integration of advanced nanomaterials, such as carbon nanotubes and graphene, is improving the sensing capabilities of implantable biosensors while maintaining biocompatibility. These nanomaterials offer enhanced sensitivity, selectivity, and stability, which leads to more accurate monitoring of cardiac biomarkers (Ghorbanizamani, F., 2023).

Another focus of research is wireless power transfer and communication, with techniques like inductive coupling and radiofrequency communication being optimized to eliminate the need for batteries and wired connections, allowing for more reliable operation within the body (Lu et al., 2023). Flexible and conformal designs are also gaining attention, as these designs better integrate with the complex geometries of cardiac tissues. This not only improves patient comfort but also reduces the risk of device migration and enhances signal quality by minimizing motion artifacts (Ghorbanizamani, F. et al., 2023). Furthermore, advancements in sensor design and integration are leading to the development of multifunctional and multimodal implantable biosensors. These devices can simultaneously monitor multiple cardiac parameters, such as electrical activity, pressure, and biochemical markers, providing a comprehensive assessment of heart health (Yogev D et al., 2023).

9.2. Potential Advancements and Impact on Long-Term Cardiac Health Monitoring

As implantable biosensor technologies continue to evolve, their impact on long-term cardiac health monitoring is expected to be significant: **Early detection and prevention of cardiac events:** Implantable biosensors can enable the early detection of cardiac abnormalities, allowing for timely interventions and potentially preventing the development of more severe conditions. This can lead to improved patient outcomes and reduced healthcare costs associated with managing advanced stages of heart disease (Yogev D et al., 2023). **Personalized and adaptive treatment plans:** The continuous data provided by implantable biosensors can help healthcare providers develop personalized treatment plans that adapt to each patient's specific needs. By monitoring the effectiveness of therapies in real-time, clinicians can make informed decisions to optimize patient care (Ghorbanizamani, F. et al., 2023). **Improved patient quality of life:** Implantable biosensors can enhance patient quality of life by reducing the need for frequent hospital visits and enabling patients to actively participate in their own health management. The ability to continuously monitor cardiac health can provide peace of mind and allow patients to engage in daily activities with greater confidence (Yogev D et al., 2023).,**Reduced healthcare costs:** The early detection and prevention of cardiac events, along with the potential for reduced hospitalizations and improved patient outcomes, can lead to significant cost savings for the healthcare system. Implantable biosensors can help shift the focus from reactive to proactive care, reducing the burden on healthcare resources (Alam, F. et al., 2024).

10. Conclusion

Implantable biosensors hold great promise for revolutionizing long-term cardiac health monitoring. These devices leverage advanced materials, sensor technologies, and wireless communication capabilities to provide continuous, real-time data on various cardiac parameters, enabling early detection of abnormalities and timely interventions.

The development of biodegradable and biocompatible materials has been a significant advancement, reducing the need for surgical removal and minimizing long-term complications. Integrating multifunctional sensing capabilities, such as pressure, pH, and biochemical markers, provides a comprehensive assessment of heart health. Advancements in wireless power transfer and communication further enhance the usability and patient comfort of these devices.

The clinical applications of implantable biosensors have demonstrated their effectiveness in managing chronic conditions like hypertension and heart failure. By enabling continuous monitoring, these devices can predict exacerbations, reduce hospitalizations, and improve patient outcomes. Moreover, the real-time data generated by implantable biosensors empowers patients to actively participate in their health management, enhancing their quality of life.

Despite the promising advancements, challenges remain in ensuring sensor accuracy, stability, and long-term reliability. Integrating these devices into existing healthcare systems and addressing ethical considerations related to data privacy and patient acceptance are also crucial for widespread adoption. Ongoing research into emerging technologies, such as flexible designs, energy harvesting, and artificial intelligence-based data analysis,

https://doi.org/10.25163/biosensors.117330

aims to overcome these hurdles and further advance the field of implantable biosensors for cardiac health monitoring.

In conclusion, implantable biosensors represent a transformative approach to personalized healthcare, offering the potential to revolutionize the management of cardiac diseases. As research continues to push the boundaries of what is possible, these devices are poised to play a pivotal role in improving patient outcomes, reducing healthcare costs, and shaping the future of cardiac care.

Author contributions

A.A.A. and M.R. conceptualized the study and led the research design. H.A.R. contributed to data analysis and drafting the manuscript, while M.A.D. assisted with methodology and review. All authors reviewed and approved the final version of the manuscript.

Acknowledgment

Author was grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Alam, F., Ahmed, M. A., Jalal, A., Siddiquee, I., Adury, R., Hossain, G., & Pala, N. (2024). Recent progress and challenges of implantable biodegradable biosensors. Micromachines, 15(4), 475. https://doi.org/10.3390/mi15040475

Awad K, Weiss R, Yunus A, Bittrick JM, Nekkanti R, Houmsse M, Okabe T, Adamson T, Miller C, Alawwa AK. BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study. BMC Cardiovasc Disord. 2020 Apr 15;20(1):171. Doi: 10.1186/s12872-020-01439-8.

Batchinsky, A. I., Cancio, L. C., Salinas, J., Kuusela, T., Cooke, W. H., Wang, J. J., ... & Holcomb, J. B. (2007). Prehospital loss of R-to-R interval complexity is associated with mortality in trauma patients. The Journal of trauma, 63(3), 512-518.

Bayoumy, K., Gaber, M., Elshafeey, A. et al. Smart wearable devices in cardiovascular care: where we are and how to move forward. Nat Rev Cardiol 18, 581–599 (2021). https://doi.org/10.1038/s41569-021-00522-7

Chowdhury, A. H., Jafarizadeh, B., Baboukani, A. R., Pala, N., & Wang, C. (2023). Monitoring and analysis of cardiovascular pulse waveforms using flexible capacitive and piezoresistive pressure sensors and machine learning perspective. Biosensors & Bioelectronics/Biosensors & Bioelectronics (Online), 237, 115449. https://doi.org/10.1016/j.bios.2023.115449.

Dervisevic, M., Alba, M., Prieto-Simon, B., & Voelcker, N. H. (2020). Skin in the diagnostics game: Wearable biosensor nano- and microsystems for medical diagnostics. Nano Today, 30, 100828. https://doi.org/10.1016/j.nantod.2019.100828

Edwards, S. J., Wakefield, V., Jhita, T., Kew, K. M., Cain, P., & Marceniuk, G. (2020). Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation. HTA on DVD/Health Technology Assessment, 24(5), 1–184. https://doi.org/10.3310/hta24050

Gerdan, Z., Saylan, Y., & Denizli, A. (2024). Biosensing platforms for cardiac biomarker detection. ACS Omega, 9(9), 9946–9960. https://doi.org/10.1021/acsomega.3c06571

Ghorbanizamani, F., Moulahoum, H., Celik, E. G., & Timur, S. (2023). Material Design in Implantable Biosensors toward Future Personalized Diagnostics and Treatments. Applied Sciences, 13(7), 4630. https://doi.org/10.3390/app13074630

Gray, M., Meehan, J., Ward, C., Langdon, S., Kunkler, I., Murray, A., & Argyle, D. (2018). Implantable biosensors and their contribution to the future of precision medicine. The Veterinary Journal, 239, 21–29. https://doi.org/10.1016/j.tvjl.2018.07.011

Gunnerson, K. J., Saul, M., He, S., & Kellum, J. A. (2006). Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. Critical care, 10(1), R22.

Hafeman, D. G., Parce, J. W., & McConnell, H. M. (1988). Light-Addressable potentiometric sensor for biochemical systems. Science, 240(4856), 1182–1185. https://doi.org/10.1126/science.3375810

Hammond JL, Formisano N, Estrela P, Carrara S, Tkac J. Electrochemical biosensors and nanobiosensors. Essays Biochem. 2016;60(1):69-80. doi: 10.1042/EBC20150008.

He S, Yuan Y, Nag A, Feng S, Afsarmanesh N, Han T, Mukhopadhyay SC, Organ DR. A Review on the Use of Impedimetric Sensors for the Inspection of Food Quality. Int J Environ Res Public Health. 2020 ;17(14):5220. Doi: 10.3390/ijerph17145220.

Hess, J. W. (1964). Serum creatine phosphokinase (CPK) activity in disorders of heart and skeletal muscle. Annals of Internal Medicine, 61(6), 1015. https://doi.org/10.7326/0003-4819-61-6-1015

Huang, S., Liu, Y., Zhao, Y., Ren, Z., & Guo, C. F. (2018). Flexible Electronics: Stretchable electrodes and their future. Advanced Functional Materials, 29(6). https://doi.org/10.1002/adfm.201805924

Huntgeburth M, Hohmann C, Ewert P, Freilinger S, Nagdyman N, Neidenbach R, Pieper L, Pieringer F, Lennerz C, Kaemmerer H, Kolb C. Implantable loop recorder for monitoring patients with congenital heart disease. Cardiovasc Diagn Ther. 2021 ;11(6):1334-1343. Doi: 10.21037/cdt-20-677.

Iqbal, S. M. A., Mahgoub, I., Du, E., Leavitt, M. A., & Asghar, W. (2021). Advances in healthcare wearable devices. Npj Flexible Electronics, 5(1). https://doi.org/10.1038/s41528-021-00107-x

Jaime FJ, Muñoz A, Rodríguez-Gómez F, Jerez-Calero A. Strengthening Privacy and Data Security in Biomedical Microelectromechanical Systems by IoT Communication Security and Protection in Smart Healthcare. Sensors (Basel). 2023 Nov 3;23(21):8944. Doi: 10.3390/s23218944.

Kakria P, Tripathi NK, Kitipawang P. A Real-Time Health Monitoring System for Remote Cardiac Patients Using Smartphone and Wearable Sensors. Int J Telemed Appl. 2015;2015:373474. Doi: 10.1155/2015/373474.

Karimian, N., Vagin, M., Zavar, M. H. A., Chamsaz, M., Turner, A. P., & Tiwari, A. (2013). An ultrasensitive molecularly-imprinted human cardiac troponin sensor. Biosensors & Bioelectronics/Biosensors & Bioelectronics (Online), 50, 492–498. https://doi.org/10.1016/j.bios.2013.07.013

Kim, H., Rigo, B., Wong, G., Lee, Y. J., & Yeo, W. (2023). Advances in wireless, batteryless, implantable electronics for Real-Time, continuous physiological monitoring. Nano-Micro Letters, 16(1). https://doi.org/10.1007/s40820-023-01272-6.

Kim, J., Lee, H., & Park, J. (2022). "Feasibility of Continuous Glucose Monitoring Systems for Cardiac Health Assessment." Journal of Cardiology, 78(4), 456-463.

Kim, S., Malik, J., Seo, J. M., Cho, Y. M., & Bien, F. (2022). Subcutaneously implantable electromagnetic biosensor system for continuous glucose monitoring. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-22128-w.

Kraut, J. A., & Madias, N. E. (2014). Lactic acidosis. New England Journal of Medicine, 371(24), 2309-2319.

Lee, C., & Wong, M. (2024). "Continuous Glucose Monitoring in Post-Operative Cardiac Care: A Systematic Review." Journal of Clinical Monitoring and Computing, 38(1), 67-78.

Lin, J., Fu, R., Zhong, X., Yu, P., Tan, G. Li, W., Zhang, H., Li, Y., Zhou, L., & Ning, C. (2021). Wearable sensors and devices for real-time cardiovascular disease monitoring. Cell Reports Physical Science, 2(8), 100541. https://doi.org/10.1016/j.xcrp.2021.100541

Liu, G., Lv, Z., Batool, S., Li, M., Zhao, P., Guo, L., Wang, Y., Zhou, Y., & Han, S. (2023). Biocompatible Material-Based flexible biosensors: from materials design to Wearable/Implantable devices and integrated sensing systems. Small,19(27). https://doi.org/10.1002/smll.202207879.

Lu T, Ji S, Jin W, Yang Q, Luo Q, Ren TL. Biocompatible and Long-Term Monitoring Strategies of Wearable, Ingestible and Implantable Biosensors: Reform the Next Generation Healthcare. Sensors (Basel). 2023 Mar 9;23(6):2991. doi: 10.3390/s23062991.

Malitesta, C., Palmisano, F., Torsi, L., & Zambonin, P. G. (1990). Glucose fast-response amperometric sensor based on glucose oxidase immobilized in an electropolymerized poly(o-phenylenediamine) film. Analytical Chemistry, 62(24), 2735–2740. https://doi.org/10.1021/ac00223a016

Mathieu Lemay, Mattia Bertschi, Josep Sola, Philippe Renevey, Elsa Genzoni, Martin Proença, Damien Ferrario, Fabian Braun, Jakub Parak, Ilkka Korhonen, Chapter 18 - Applications of Optical Cardiovascular Monitoring, Editor(s): Edward Sazonov, Wearable Sensors (Second Edition), Academic Press, 2021, Pages 487-517, ISBN 9780128192467, https://doi.org/10.1016/B978-0-12-819246-7.00018-8.

Mcshane, M. J., Biswas, A., Nagaraja, A., Cote, G. L., & Pishko, M. V. (2015, December 9). WO2017100680A1 - Implantable biosensors-Google Patents. https://patents.google.com/patent/WO2017100680A1/en.

Moshawrab M, Adda M, Bouzouane A, Ibrahim H, Raad A. Smart Wearables for the Detection of Cardiovascular Diseases: A Systematic Literature Review. Sensors (Basel). 2023;23(2):828. doi: 10.3390/s23020828.

N. Akouz, A. El Ghazi, M. Zourhri, S. Hamida, B. Cherradi and A. Raihani, "A Comprehensive Review on Monitoring Sensors for Cardiovascular Disease Prevention and Management," 2023 3rd International Conference on Innovative Research in Applied Science, Engineering and Technology (IRASET), Mohammedia, Morocco, 2023, pp. 1-8, doi: 10.1109/IRASET57153.2023.10152939.

Nash KE, Ong KG, Guldberg RE. Implantable biosensors for musculoskeletal health. Connect Tissue Res. 2022;63(3):228-242. doi: 10.1080/03008207.2022.2041002.

Nath, P., Mahtaba, K. R., & Ray, A. (2023). Fluorescence-Based portable assays for detection of biological and chemical analytes. Sensors, 23(11), 5053. https://doi.org/10.3390/s23115053

Nishikimi, T., Maeda, N., & Matsuoka, H. (2006). The role of natriuretic peptides in cardioprotection. Cardiovascular Research, 69(2), 318–328. https://doi.org/10.1016/j.cardiores.2005.10.001

Omar, R., Saliba, W., Khatib, M., Zheng, Y., Pieters, C., Oved, H., Silberman, E., Zohar, O., Hu, Z., Kloper, V., Broza, Y. Y., Dvir, T., Dana, A. G., Wang, Y., & Haick, H. (2024). Biodegradable, biocompatible, and implantable multifunctional sensing platform for cardiac monitoring. ACS Sensors, 9(1), 126–138. https://doi.org/10.1021/acssensors.3c01755

Polat EO, Cetin MM, Tabak AF, Bilget Güven E, Uysal BÖ, Arsan T, Kabbani A, Hamed H, Gül SB. Transducer Technologies for Biosensors and Their Wearable Applications. Biosensors (Basel). 2022;12(6):385. doi: 10.3390/bios12060385.

Rixen, D., & Siegel, J. H. (2005). Bench-to-bedside review: oxygen debt and its metabolic correlates as quantifiers of the severity of hemorrhagic and post-traumatic shock. Critical Care, 9(5), 441.

Rodrigues D, Barbosa AI, Rebelo R, Kwon IK, Reis RL, Correlo VM. Skin-Integrated Wearable Systems and Implantable Biosensors: A Comprehensive Review. Biosensors (Basel). 2020 Jul 21;10(7):79. doi: 10.3390/bios10070079.

Runjie He, Lingyu Shen, Zhuo Wang, Guoqing Wang, Hang Qu, Xuehao Hu, Rui Min, Optical fiber sensors for heart rate monitoring: A review of mechanisms and applications, Results in Optics, Volume 11, 2023, 100386, ISSN 2666-9501,

Sandulescu, R., Tertis, M., Cristea, C., & Bodoki, E. (2015). New materials for the construction of electrochemical biosensors. In InTech eBooks. https://doi.org/10.5772/60510.

Schrittwieser, Stefan, Beatriz Pelaz, Wolfgang J. Parak, Sergio Lentijo-Mozo, Katerina Soulantica, Jan Dieckhoff, Frank Ludwig, Annegret Guenther, Andreas Tschöpe, and Joerg Schotter. 2016. "Homogeneous Biosensing Based on Magnetic Particle Labels" Sensors 16, no. 6: 828. https://doi.org/10.3390/s16060828.

Smith, R., & Johnson, T. (2023). "Integrating CGMS Data with Cardiac Monitoring: A Comprehensive Review." Cardiovascular Research, 119(2), 234-245.

Solaro, R. J. (1999). Troponin I, Stunning, Hypertrophy, and failure of the heart. Circulation Research, 84(1), 122–124. https://doi.org/10.1161/01.res.84.1.122.

Song, M., Lin, X., Peng, Z., Xu, S., Jin, L., Zheng, X., & Luo, H. (2021). Materials and methods of biosensor interfaces with stability. Frontiers in Materials, 7. https://doi.org/10.3389/fmats.2020.583739.

Suvrajyoti Mishra, Smita Mohanty, and Ananthakumar Ramadoss. Functionality of Flexible Pressure Sensors in Cardiovascular Health Monitoring: A Review. ACS Sensors 2022 7 (9), 2495-2520. DOI: 10.1021/acssensors.2c00942

Tang, C., Liu, Z., & Li, L. (2022). Mechanical sensors for cardiovascular monitoring: from Battery-Powered to Self-Powered. Biosensors, 12(8), 651. https://doi.org/10.3390/bios12080651.

Thoelen, R., Vansweevelt, R., Duchateau, J., Horemans, F., D'Haen, J., Lutsen, L., Vanderzande, D., Ameloot, M., vandeVen, M., & Cleij, T. (2008). A MIP-based impedimetric sensor for the detection of low-MW molecules. Biosensors & Bioelectronics/Biosensors & Bioelectronics (Online), 23(6), 913–918. https://doi.org/10.1016/j.bios.2007.08.020

Tran, D. H., & Wang, Z. V. (2019). Glucose Metabolism in Cardiac Hypertrophy and Heart Failure. Journal of the American Heart Association. Cardiovascular and Cerebrovascular Disease, 8(12). https://doi.org/10.1161/jaha.119.012673

Yang, Y., Lu, Y., Gupta, A. K., & Lin, S. (2022). Real-time impedimetric detection of cardiac troponin I using ITO-coated vertically aligned silicon nanowires. Materials Letters, 311, 131575. https://doi.org/10.1016/j.matlet.2021.131575

Yogev D, Goldberg T, Arami A, Tejman-Yarden S, Winkler TE, Maoz BM. Current state of the art and future directions for implantable sensors in medical technology: Clinical needs and engineering challenges. APL Bioeng. 2023 Sep 27;7(3):031506. doi: 10.1063/5.0152290.

Zha B, Wang Z, Li L, Hu X, Ortega B, Li X, Min R. Wearable cardiorespiratory monitoring with stretchable elastomer optical fiber. Biomed Opt Express. 2023;14(5):2260-2275. doi: 10.1364/BOE.490034.

Zhang T, Liu N, Xu J, Liu Z, Zhou Y, Yang Y, Li S, Huang Y, Jiang S. Flexible electronics for cardiovascular healthcare monitoring. Innovation (Camb). 2023 ;4(5):100485. doi: 10.1016/j.xinn.2023.100485.

Zhang, Y., & Liu, X. (2023). "Advancements in Continuous Glucose Monitoring Technologies for Cardiovascular Applications." Biosensors and Bioelectronics, 224, 114-121.